pBabe-Kras G12C Citations (13)
Originally described in: Mutant Ras ConstructsUnpublished
Articles Citing pBabe-Kras G12C
| Articles |
|---|
| RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24. PubMed |
| Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis. Wang ZD, Wei SQ, Wang QY. Am J Cancer Res. 2015 Oct 15;5(11):3339-49. eCollection 2015. PubMed |
| Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Inoue S, Hirota Y, Ueno T, Fukui Y, Yoshida E, Hayashi T, Kojima S, Takeyama R, Hashimoto T, Kiyono T, Ikemura M, Taguchi A, Tanaka T, Tanaka Y, Sakata S, Takeuchi K, Muraoka A, Osuka S, Saito T, Oda K, Osuga Y, Terao Y, Kawazu M, Mano H. Nat Commun. 2019 Dec 19;10(1):5785. doi: 10.1038/s41467-019-13708-y. PubMed |
| A CRISPR-Cas9 repressor for epigenetic silencing of KRAS. Liu J, Sun M, Cho KB, Gao X, Guo B. Pharmacol Res. 2021 Feb;164:105304. doi: 10.1016/j.phrs.2020.105304. Epub 2020 Nov 14. PubMed |
| Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation. Sad K, Parashar P, Tripathi P, Hungyo H, Sistla R, Soni R, Tandon V. Free Radic Biol Med. 2021 Dec;177:299-312. doi: 10.1016/j.freeradbiomed.2021.11.001. Epub 2021 Nov 3. PubMed |
| Oncogenic KRAS G12C: Kinetic and redox characterization of covalent inhibition. Huynh MV, Parsonage D, Forshaw TE, Chirasani VR, Hobbs GA, Wu H, Lee J, Furdui CM, Poole LB, Campbell SL. J Biol Chem. 2022 Aug;298(8):102186. doi: 10.1016/j.jbc.2022.102186. Epub 2022 Jun 24. PubMed |
| Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways. Tripathi P, Soni R, Antra, Tandon V. Free Radic Biol Med. 2022 Sep;190:351-362. doi: 10.1016/j.freeradbiomed.2022.08.015. Epub 2022 Aug 12. PubMed |
| NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. Ramakrishnan G, Parajuli P, Singh P, Friend C, Hurwitz E, Prunier C, Razzaque MS, Xu K, Atfi A. Cell Rep. 2022 Nov 8;41(6):111623. doi: 10.1016/j.celrep.2022.111623. PubMed |
| Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer. Shin DH, Jo JY, Choi M, Kim KH, Bae YK, Kim SS. Exp Mol Med. 2023 Oct;55(10):2220-2237. doi: 10.1038/s12276-023-01091-0. Epub 2023 Oct 2. PubMed |
| The pro-oncogenic noncanonical activity of a RAS*GTP:RanGAP1 complex facilitates nuclear protein export. Tripathi BK, Hirsh NH, Qian X, Durkin ME, Wang D, Papageorge AG, Lake R, Evrard YA, Marcus AI, Ramalingam SS, Dasso M, Vousden KH, Doroshow JH, Walters KJ, Lowy DR. Nat Cancer. 2024 Dec;5(12):1902-1918. doi: 10.1038/s43018-024-00847-5. Epub 2024 Nov 11. PubMed |
| A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. Foote JB, Mattox TE, Keeton AB, Chen X, Smith FT, Berry K, Holmes TW, Wang J, Huang CH, Ward A, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G, Nurmemmedov E, Babic I, Gaponeko V, Abdelkarim H, Boyd MR, Gorman G, Manne U, Bae S, El-Rayes BF, Piazza GA. Cancer Res. 2025 Mar 3;85(5):956-972. doi: 10.1158/0008-5472.CAN-24-0323. PubMed |
| Oncogenic KRAS addiction states differentially influence MTH1 expression and 8-oxodGTPase activity in lung adenocarcinoma. Mateo-Victoriano B, Samaranayake GJ, Pokharel S, Sahayanathan GJ, Jayaraj C, Troccoli CI, Watson DC, Mohsen MG, Guo Y, Kool ET, Rai P. Redox Biol. 2025 May;82:103610. doi: 10.1016/j.redox.2025.103610. Epub 2025 Mar 23. PubMed |
| Targeting TGF-beta-Smad2/3-JNK1-mediated SIRT1 activity overcomes the chemoresistance of KRAS mutation lung cancer. Shin DH, Choi M, Han C, Kim SS. Exp Mol Med. 2025 Sep;57(9):2022-2039. doi: 10.1038/s12276-025-01536-8. Epub 2025 Sep 12. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.